Kura Oncology CMO Leoni Mollie Sells 41,250 Shares

What Happened Leoni Mollie, Chief Medical Officer of Kura Oncology (KURA), sold a total of 41,250 shares in two open-market transactions: 12,448 shares on 2026-09-28 at $10.50 (reported value $130,670) and 28,802 shares on 2026-09-29 at a weighted average $10.75 (reported value $309,567). Total proceeds reported for the two disposals are approximately $440,237. These were sales (not purchases).

Key Details

• Dates & prices: 2026-09-28 — 12,448 shares @ $10.50 (reported $130,670); 2026-09-29 — 28,802 shares @ $10.75 weighted avg (reported $309,567). F3 notes the 9/29 trades executed at prices ranging $10.53–$10.89; the $10.75 figure is the weighted average.
• Source of shares: The shares sold were acquired upon vesting of performance-based restricted stock units (PSUs) that vested on 2026-09-27.
• Plan/authorization: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2026-03-19 (F2).
• Tax withholding: A portion of the shares were sold as a sell-to-cover for taxes related to the vesting of 1/6th of the underlying PSUs (F1).
• Shares owned after transaction: Not specified in the information provided.
• Filing timeliness: Form filed 2026-09-29 reporting transactions on 9/28 and 9/29; no indication in the provided filing that this was late.

Context The disposals stem from the vesting of PSUs tied to development milestones (each PSU converts to one share if milestones and related anniversaries are met). The reported sales include routine sell-to-cover tax withholding and were executed under a pre-established 10b5-1 plan. These are insider sales (routine liquidity/tax-related) rather than insider purchases, which some investors view as stronger signals of bullish insider conviction.